Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 166

1.

Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations.

Gaughan EM, Cryer SK, Yeap BY, Jackman DM, Costa DB.

Lung Cancer. 2013 Mar;79(3):193-7. doi: 10.1016/j.lungcan.2012.12.002. Epub 2012 Dec 27.

2.

Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice.

Yamaguchi N, Vanderlaan PA, Folch E, Boucher DH, Canepa HM, Kent MS, Gangadharan SP, Majid A, Kocher ON, Goldstein MA, Huberman MS, Costa DB.

Lung Cancer. 2013 Oct;82(1):31-7. doi: 10.1016/j.lungcan.2013.07.013. Epub 2013 Aug 7.

3.

Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.

Kim HR, Shim HS, Chung JH, Lee YJ, Hong YK, Rha SY, Kim SH, Ha SJ, Kim SK, Chung KY, Soo R, Kim JH, Cho BC.

Cancer. 2012 Feb 1;118(3):729-39. doi: 10.1002/cncr.26311. Epub 2011 Jun 30.

4.

Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.

Rangachari D, Yamaguchi N, VanderLaan PA, Folch E, Mahadevan A, Floyd SR, Uhlmann EJ, Wong ET, Dahlberg SE, Huberman MS, Costa DB.

Lung Cancer. 2015 Apr;88(1):108-11. doi: 10.1016/j.lungcan.2015.01.020. Epub 2015 Feb 4.

5.

Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer.

Vanderlaan PA, Yamaguchi N, Folch E, Boucher DH, Kent MS, Gangadharan SP, Majid A, Goldstein MA, Huberman MS, Kocher ON, Costa DB.

Lung Cancer. 2014 Apr;84(1):39-44. doi: 10.1016/j.lungcan.2014.01.013. Epub 2014 Jan 28.

6.

Molecular alterations in non-small cell lung carcinomas of the young.

VandenBussche CJ, Illei PB, Lin MT, Ettinger DS, Maleki Z.

Hum Pathol. 2014 Dec;45(12):2379-87. doi: 10.1016/j.humpath.2014.08.005. Epub 2014 Sep 2.

PMID:
25288236
7.

Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma.

Sun JM, Lira M, Pandya K, Choi YL, Ahn JS, Mao M, Han J, Park K, Ahn MJ, Kim J.

Lung Cancer. 2014 Feb;83(2):259-64. doi: 10.1016/j.lungcan.2013.11.009. Epub 2013 Nov 20.

PMID:
24300132
8.

Chronic Obstructive Pulmonary Disease-Related Non-Small-Cell Lung Cancer Exhibits a Low Prevalence of EGFR and ALK Driver Mutations.

Lim JU, Yeo CD, Rhee CK, Kim YH, Park CK, Kim JS, Kim JW, Lee SH, Kim SJ, Yoon HK, Kim TJ, Lee KY.

PLoS One. 2015 Nov 10;10(11):e0142306. doi: 10.1371/journal.pone.0142306. eCollection 2015.

9.

Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer.

Li Y, Li Y, Yang T, Wei S, Wang J, Wang M, Wang Y, Zhou Q, Liu H, Chen J.

PLoS One. 2013;8(1):e52093. doi: 10.1371/journal.pone.0052093. Epub 2013 Jan 14.

10.

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac LR, Kwak EL, Lynch TJ, Iafrate AJ.

J Clin Oncol. 2009 Sep 10;27(26):4247-53. doi: 10.1200/JCO.2009.22.6993. Epub 2009 Aug 10.

11.

Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.

Zhang Y, Sun Y, Pan Y, Li C, Shen L, Li Y, Luo X, Ye T, Wang R, Hu H, Li H, Wang L, Pao W, Chen H.

Clin Cancer Res. 2012 Apr 1;18(7):1947-53. doi: 10.1158/1078-0432.CCR-11-2511. Epub 2012 Feb 8.

12.

Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non-small-cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage.

Kim TJ, Park CK, Yeo CD, Park K, Rhee CK, Kim J, Kim SJ, Lee SH, Lee KY, Yoon HK.

J Surg Oncol. 2014 Sep;110(3):245-51. doi: 10.1002/jso.23646. Epub 2014 May 29.

PMID:
24888607
13.

The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.

Qu Y, Che N, Zhao D, Zhang C, Su D, Zhou L, Zhang L, Wang C, Zhang H, Wei L.

Tumour Biol. 2015 Aug;36(8):6417-24. doi: 10.1007/s13277-015-3331-4. Epub 2015 Mar 28.

PMID:
25813151
14.

The ALK translocation in advanced non-small-cell lung carcinomas: preapproval testing experience at a single cancer centre.

Conde E, Angulo B, Izquierdo E, Muñoz L, Suárez-Gauthier A, Plaza C, Dominguez N, Torres M, Madrigal L, Rubio-Viqueira B, Belda-Iniesta C, Hidalgo M, López-Ríos F.

Histopathology. 2013 Mar;62(4):609-16. doi: 10.1111/his.12037. Epub 2013 Feb 5.

15.

High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.

Sun PL, Seol H, Lee HJ, Yoo SB, Kim H, Xu X, Jheon S, Lee CT, Lee JS, Chung JH.

J Thorac Oncol. 2012 Feb;7(2):323-30. doi: 10.1097/JTO.0b013e3182381515.

16.

Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.

Metro G, Chiari R, Bennati C, Cenci M, Ricciuti B, Puma F, Flacco A, Rebonato A, Giannarelli D, Ludovini V, Bellezza G, Ferolla P, Minotti V, Crinò L.

Clin Lung Cancer. 2014 Jan;15(1):86-92. doi: 10.1016/j.cllc.2013.08.002. Epub 2013 Oct 17.

PMID:
24139827
17.

Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.

Mounawar M, Mukeria A, Le Calvez F, Hung RJ, Renard H, Cortot A, Bollart C, Zaridze D, Brennan P, Boffetta P, Brambilla E, Hainaut P.

Cancer Res. 2007 Jun 15;67(12):5667-72.

18.

CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer.

Rizzo S, Petrella F, Buscarino V, De Maria F, Raimondi S, Barberis M, Fumagalli C, Spitaleri G, Rampinelli C, De Marinis F, Spaggiari L, Bellomi M.

Eur Radiol. 2016 Jan;26(1):32-42. doi: 10.1007/s00330-015-3814-0. Epub 2015 May 9.

PMID:
25956936
19.

The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.

Kim HR, Lim SM, Kim HJ, Hwang SK, Park JK, Shin E, Bae MK, Ou SH, Wang J, Jewell SS, Kang DR, Soo RA, Haack H, Kim JH, Shim HS, Cho BC.

Ann Oncol. 2013 Sep;24(9):2364-70. doi: 10.1093/annonc/mdt220. Epub 2013 Jun 19.

PMID:
23788756
20.

Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma.

Kim MH, Shim HS, Kang DR, Jung JY, Lee CY, Kim DJ, Lee JG, Bae MK, Kim HR, Lim SM, Kim EY, Park JS, Chung KY, Kim HJ, Kim JH, Cho BC.

Lung Cancer. 2014 Mar;83(3):389-95. doi: 10.1016/j.lungcan.2014.01.003. Epub 2014 Jan 14.

PMID:
24462463

Supplemental Content

Support Center